Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase NA 6Phase 3 3Phase 2/3 2Phase 1/2 2Phase 4 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 32INDUSTRY 12OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1

Interventions

Bevacizumab 4Zoledronic Acid 3Cisplatin 3Capecitabine 3spartalizumab 2anlotinib 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Metformin 2Letrozole 2Drug Therapy 2vosaroxin 1venetoclax 1tislelizumab 1pembrolizumab 1enzalutamide 1empagliflozin 1atezolizumab 1apatinib 1abiraterone 1XELOX 1Vacuum Curettage 1Tyrosine Kinase Inhibitors 1Tuberculin 1Sorafenib 1Sodium Chloride 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER_GOV × Drug Therapy × Clear all
NCT07472153 2026-03-16

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03957733 2022-04-06

Phase II/III Study to Assess the Efficacy of Neoadjuvant Consolidation Chemotherapy in Rectal Cancer Patients.

King Abdullah Medical City

Phase 2/3 Unknown
338 enrolled
Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡